Access Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 128

Access Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Access Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Access Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Access Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Access Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Access Pharmaceuticals, Inc. - Brief Access Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Access Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Access Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Access Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Access Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Access Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Access Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Access Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Access Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc. - Key Therapeutics; Access Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Access Pharmaceuticals, Inc. - News; Access Pharmaceuticals, Inc. - Latest Updates; Access Pharmaceuticals, Inc. - Pipeline; Access Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Access Pharmaceuticals, Inc. Snapshot
Access Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Access Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Access Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Access Pharmaceuticals, Inc. – Pipeline Products Glance
Access Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Access Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Access Pharmaceuticals, Inc. – Drug Profiles
Alchemix
Product Description
Mechanism of Action
R&D Progress
Amlexanox
Product Description
Mechanism of Action
R&D Progress
Angiolix
Product Description
Mechanism of Action
R&D Progress
CobOral hGH
Product Description
Mechanism of Action
R&D Progress
CobOral Insulin
Product Description
Mechanism of Action
R&D Progress
EcoNail
Product Description
Mechanism of Action
R&D Progress
Oral Infertility Drugs
Product Description
Mechanism of Action
R&D Progress
Prodrax
Product Description
Mechanism of Action
R&D Progress
ProLindac
Product Description
Mechanism of Action
R&D Progress
ProLindac + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Sodium Phenylbutyrate
Product Description
Mechanism of Action
R&D Progress
Thiarabine
Product Description
Mechanism of Action
R&D Progress
Access Pharmaceuticals, Inc. – Pipeline Analysis
Access Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Access Pharmaceuticals, Inc. - Pipeline Products By Target
Access Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Access Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Access Pharmaceuticals, Inc. – Recent Pipeline Updates
Access Pharmaceuticals, Inc. - Dormant Projects
Access Pharmaceuticals, Inc. – Company Statement
Access Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 31, 2010: Real Oral Versions Of Insulin And HGH In Development
Jan 31, 2007: Somanta Announces Data to Be Presented on Angiolix for Targeting Breast Cancer Stem Cells at Stem Cells and Cancer Conference
Mar 30, 2010: Access Pharma Launches Clinical Development Program For Oral Insulin Product
Oct 29, 2007: Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data On ProLindac at the AACR-NCI-EORTC 'Molecular Targets And Cancer Therapeutics' Conference
Jul 28, 2011: Access Pharmaceuticals Launches MuGard Patient Reimbursement And Support Center
May 28, 2008: Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac Development at Prestigious International Symposium
Jul 27, 2010: Access Partner Launches Multi-Channel Product Marketing Program For MuGard
Nov 26, 2002: ACCESS Enters Next Phase Of Clinical Development For AP5280
Jun 26, 2008: Access Pharmaceuticals Presents New Data At International Symposium Showing Company’S Angiolix Monoclonal Antibody Has Potential To Treat Cancer By Attacking Cancer Stem Cells
Mar 26, 2010: Access' Korean Partner Gains Marketing Approval For MuGard
Feb 26, 2009: Access Pharmaceuticals Closes Acquisition Of Macrochem Corp.
Jan 26, 2009: Access Pharmaceuticals Presents The Combination Data On The Angiolix Therapeutic Monoclonal Antibody
Jul 25, 2008: MacroChem Corporation Announces Results Of Phase II Clinical Trial Of EcoNail
Apr 23, 2008: MacroChem Corporation Acquires Virium's Sodium Phenylbutyrate
Oct 22, 2008: Access Pharmaceuticals Presents ProLindac Data At The AACR-NCI-EORTC Symposium 2008
Apr 20, 2009: SpePharm Announces European Launch Of MuGard
Jul 19, 2011: TRICARE Provides Coverage For Access Pharmaceuticals's MuGard
Apr 19, 2007: Somanta Presents Positive Data From Alchemix On Multiple Cancer Cell Lines At Prostate Cancer Update Conference
Dec 17, 2008: MacroChem's Pexiganan Phase III Clinical Trials Results Published In December Issue Of CID
Jun 17, 2011: Access Pharmaceuticals Receives Letter Of Acceptance For MuGard Filing From SFDA Of China
Apr 17, 2008: Access Pharmaceuticals Announces New Data on Angiolix
Nov 16, 2004: MacroChem Corporation (MCHM) Announces The Successful Results From EcoNail Phase I Clinical Trial
Oct 15, 2010: Access Receives Initial MuGard Prescriptions And Reimbursements
Sep 14, 2010: Access Receives Initial Purchase Order For MuGard In North America
Jul 14, 2011: Access Pharmaceuticals MuGard Added To CVS Caremark's Pharmacy Benefit Network
Nov 13, 2010: Access Pharmaceuticals Presents CobOral Insulin Research At 10th Annual Diabetes Technology Meeting On November
Nov 13, 1998: MacroChem's Pexiganan Shows Activity Against Broad Spectrum of Pathogens.
Mar 13, 2008: MacroChem Announces Presentation Of Pexiganan Phase III Study Results For Topical Treatment Of Diabetic Foot Infection
Oct 11, 2010: Accesss's MuGard Provides Significant Improvement Of Oral Mucositis In Over 75% Of Patients In European Clinical Experience
Apr 11, 2007: Macrochem Completes Patient Enrollment For Phase II Trial Of Econail For Treatment Of Onychomycosis
Mar 11, 2010: Access Pharmaceuticals Reports Significant Oral Bioavailability Of Cobalamin Oral Insulin In Additional Studies
Oct 10, 2010: SpePharm Presents European Clinical Experience With MuGard At ESMO 2010 Congress
May 10, 2011: Access Pharmaceuticals Cobraxane Program Displays Significant Advantage Over Commercially-Available Paclitaxel Protein-Bound Particles
Apr 10, 2008: Access Pharmaceuticals Presents New Data on ProLindac At The 2009 AACR Annual Meeting
Aug 09, 2011: Access Pharmaceuticals Expands MuGard Specialty Pharmacy Reach With Community Specialty Pharmacy Network
Jun 09, 2006: Access Pharmaceuticals Announces Dosing Of ProLindac In First Patient In Its Phase II Trial
May 09, 2001: Access Updates Clinical Progress With AP5280 Polymer Platinate
Feb 09, 2011: Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential
Jul 07, 2009: ACCESS's Thiarabine Demonstrates A Reduction Of Both Inflammatory And Erosive Disease Parameters In Rheumatoid Arthritis
Jun 07, 2009: Access's Thiarabine Demonstrates A Reduction Of Both Inflammatory And Erosive Disease Parameters In Rheumatoid Arthritis
Jan 07, 2010: Access Pharmaceuticals Completes Clinical Study Enrollment Of ProLindac For The Treatment Of Ovarian Cancer
Nov 06, 2007: MacroChem Announces Positive Interim Phase II Data for EcoNail in the Treatment of Onychomycosis
Sep 06, 2007: Angiolix Is Effective In Ovarian And Breast Cancer
Mar 06, 2009: Access Pharmaceuticals Announces Positive ProLindac Phase 2 Ovarian Cancer Clinical Trial Results
Oct 04, 2006: MacroChem Corporation Initiates The Phase II Study Of EcoNail Topical Antifungal Lacquer
Jun 04, 2009: Access Pharmaceuticals Announces Publication Of Thiarabine Combination Data
Jun 04, 2007: Access and Somanta Announces Data to Be Presented on Angiolix at ASCO Oncology Conference
Dec 03, 2009: Access Pharmaceuticals Launches MuGard For The Treatment Of Oral Mucositis In Europe
Nov 03, 2010: Access Commences ProLindac Phase II Combination Clinical Trial In Platinum-Sensitive Ovarian Cancer Patients
Aug 03, 2010: Access Initiates Phase I/II Study Of Thiarabine In Patients With Hematologic Malignancies
Aug 03, 2009: Access Pharmaceuticals Provides Update On Prolindac Clinical Development Program
Aug 02, 2011: Access Pharmaceuticals MuGard Added To Humana's Pharmacy Drug Benefit Network
Jun 02, 2009: Access Pharmaceuticals Provides Update On ProLindac Phase 2 Ovarian Cancer Trial And Clinical Development Plan
Jan 01, 2003: AP5280 Announces The Commencement Of The Next Phase In The Clinical Development Of Polymer Platinate AP5280
Financial Deals Landscape
Access Pharmaceuticals, Inc., Deals Summary
Access Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Access Pharmaceuticals Enters Into Agreement With Pharmaceutical Company
Access Pharmaceuticals Enters Into Co-Development Agreement With Biopharmaceutical Company
Access Pharmaceuticals Enters Into Specialty Distribution Agreement With BioScrip
Access Pharmaceuticals Enters Into Co-Development Agreement With A Biotech Company
Access Pharmaceuticals Enters Into An Agreement With Stephen T. Sonis
Access Pharmaceuticals Enters Into Co-Marketing Agreement With iMedicor
Somanta Pharmaceuticals Signs Research Agreement With University of Bradford
Access Pharmaceuticals Enters Into Research Collaboration With Hunter-Fleming
Access Pharmaceuticals Enters Into Research Agreement With A Major Pharmaceutical Company
Somanta Enters Into Co-Development Agreement With London School Of Pharmacy
Access Pharmaceuticals Enters Into Research Collaboration With Drug Delivery Company
Merger
Somanta Merges With Bridge Oncology Products
Licensing Agreements
Southern Research Institute Enters Into Licensing Agreement With Virium Pharmaceuticals
Access Pharmaceuticals Enters Into License Agreement With JCOM And Dong-A
Access Pharmaceuticals Enters Into Licensing Agreement With Milestone Biosciences
Access Pharmaceuticals Enters Into Licensing Agreement With Jiangsu Aosaikang Pharmaceutical
Access Pharmaceuticals Enters Into Licensing Agreement With RHEI Pharmaceuticals
Access Pharmaceuticals Enters Into Licensing Agreement With SpePharm
BioProgress Enters Into Licensing Agreement With Access Pharmaceuticals
Orient Europharma Enters Into Licensing Agreement With Access Pharmaceuticals
EpiTan Enters Into Licensing Agreement With Access Pharmaceuticals
Somanta Enters Into Licensing Agreement With Advanced Cardiovascular Devices
Access Pharmaceuticals Enters Into Licensing Agreement With Wyeth Consumer Healthcare
Equity Offering
Access Pharmaceuticals Announces Private Placement Of Units For $5.2 Million
Access Pharmaceuticals Completes Private Placement Of $7.9 Million
Access Pharmaceuticals Completes Private Placement Of $6.3 Million
Access Pharmaceuticals Issues Series A Cumulative Convertible Preferred Stock For $2.73 Million
Access Pharmaceuticals Completes Private Placement Of $12.25 Million
Somanta Pharmaceuticals Completes Private Placement Of $5.9 Million
Access Pharmaceuticals Completes Private Placement Of $9.7 Million
Debt Offering
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $5 Million
Access Pharmaceuticals Completes Private Placement Of Secured Convertible Debentures For $2.63 Million
Asset Transactions
ULURU Acquires Topical Care Business From Access Pharmaceuticals
Acquisition
Access Pharmaceuticals Acquires MacroChem
MacroChem Acquires Virium Pharmaceuticals
Access Pharmaceuticals Acquires Somanta Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Access Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Access Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Access Pharmaceuticals, Inc. - Phase II, H2 2011
Access Pharmaceuticals, Inc. - Phase I, H2 2011
Access Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Access Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Access Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Access Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Access Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Access Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Access Pharmaceuticals, Inc., Subsidiaries
Access Pharmaceuticals, Inc., Deals Summary
Access Pharmaceuticals Enters Into Agreement With Pharmaceutical Company
Access Pharmaceuticals Enters Into Co-Development Agreement With Biopharmaceutical Company
Access Pharmaceuticals Enters Into Specialty Distribution Agreement With BioScrip
Access Pharmaceuticals Enters Into Co-Development Agreement With A Biotech Company
Access Pharmaceuticals Enters Into An Agreement With Stephen T. Sonis
Access Pharmaceuticals Enters Into Co-Marketing Agreement With iMedicor
Somanta Pharmaceuticals Signs Research Agreement With University of Bradford
Access Pharmaceuticals Enters Into Research Collaboration With Hunter-Fleming
Access Pharmaceuticals Enters Into Research Agreement With A Major Pharmaceutical Company
Somanta Enters Into Co-Development Agreement With London School Of Pharmacy
Access Pharmaceuticals Enters Into Research Collaboration With Drug Delivery Company
Somanta Merges With Bridge Oncology Products
Southern Research Institute Enters Into Licensing Agreement With Virium Pharmaceuticals
Access Pharmaceuticals Enters Into License Agreement With JCOM And Dong-A
Access Pharmaceuticals Enters Into Licensing Agreement With Milestone Biosciences
Access Pharmaceuticals Enters Into Licensing Agreement With Jiangsu Aosaikang Pharmaceutical
Access Pharmaceuticals Enters Into Licensing Agreement With RHEI Pharmaceuticals
Access Pharmaceuticals Enters Into Licensing Agreement With SpePharm
BioProgress Enters Into Licensing Agreement With Access Pharmaceuticals
Orient Europharma Enters Into Licensing Agreement With Access Pharmaceuticals
EpiTan Enters Into Licensing Agreement With Access Pharmaceuticals
Somanta Enters Into Licensing Agreement With Advanced Cardiovascular Devices
Access Pharmaceuticals Enters Into Licensing Agreement With Wyeth Consumer Healthcare
Access Pharmaceuticals Announces Private Placement Of Units For $5.2 Million
Access Pharmaceuticals Completes Private Placement Of $7.9 Million
Access Pharmaceuticals Completes Private Placement Of $6.3 Million
Access Pharmaceuticals Issues Series A Cumulative Convertible Preferred Stock For $2.73 Million
Access Pharmaceuticals Completes Private Placement Of $12.25 Million
Somanta Pharmaceuticals Completes Private Placement Of $5.9 Million
Access Pharmaceuticals Completes Private Placement Of $9.7 Million
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $0.5 Million
Access Pharmaceuticals Completes Private Placement Of 7.5% Convertible Notes For $5 Million
Access Pharmaceuticals Completes Private Placement Of Secured Convertible Debentures For $2.63 Million
ULURU Acquires Topical Care Business From Access Pharmaceuticals
Access Pharmaceuticals Acquires MacroChem
MacroChem Acquires Virium Pharmaceuticals
Access Pharmaceuticals Acquires Somanta Pharmaceuticals

List of Figures
Access Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Access Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Access Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Access Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Access Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Access Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Idenix Pharmaceuticals, Inc.
• Analysis of Google Inc
• SunGard - Profile - US
• US - SunGard - Company Profile
• Tellabs, Inc.
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• America's Suppliers, Inc.,(AASL) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Internet America Inc,(GEEK) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages